FDA Committee Votes Down Janssen’s Plivensia Arthritis Drug, Citing Safety Concerns

Drug Industry Daily
A A
An FDA advisory committee voted 12-to-1 against recommending approval of Janssen’s Plivensia (sirukumab) in treating rheumatoid arthritis, saying its safety profile raised too many concerns.

To View This Article:

Login

Subscribe To Drug Industry Daily